Loading the list…

Prelude Therapeutics Incorporated (PRLD)

Nasdaq · PRLD

connecting

$3.45−1.99%

Closing prices for 13 November 2026

Loading chart

Company valuation

The series is stated in the current share scale after splits; dividends are not included in the price

Volatility 90d

80.76%

Place in range

38.93%

−31.94%sector median −30.08%

Net margin

−269.75%sector median −20.85%

Operating margin

−300.56%sector median −20.96%

Current ratio

4.1

Revenue, last year

$22M

Net income, last year

−$60M

Earnings per share

−$0.73

Based on the last 12 months of reports, through 30 June 2026

The sector median covers every company in the sector on the US market, loss-making ones included.

Share count is a period average, so market cap is approximate.

How to read the figures

Market capitalisation is the value of all of a company's shares at the current price: the price of one share times the number of shares.
P/S (price / sales) is market capitalisation divided by revenue over 12 months: what the market pays for each unit of sales. Useful when there is no profit yet.
P/B (price / book) is market capitalisation divided by shareholders' equity: below one means the market values the company under its accounting assets net of debt.
ROE (return on equity) is net income over 12 months divided by shareholders' equity: how much profit the company earns on each unit of its owners' capital.
ROA (return on assets) is net income divided by total assets: how efficiently the company uses what it owns.
Net margin is the share of net income in revenue: how much profit remains from each unit of sales.
Operating margin is the share of profit from core operations in revenue, before interest and taxes.
The current ratio is current assets divided by short-term liabilities: whether the company has enough cash and inventory to pay its nearest debts.